 | • レポートコード：360iR22DE123 • 出版社/出版日：360iResearch / 2022年10月 • レポート形態：英語、PDF、239ページ • 納品方法：Eメール（受注後2-3日） • 産業分類：医療 |
| Single User（1名利用、印刷可） | ￥742,350 (USD4,949) | ▷ お問い合わせ |
| Enterprise License（企業利用、印刷可） | ￥1,492,350 (USD9,949) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 360iResearch社の本調査レポートは、2021年に108.4億ドルであった世界のマルチプレックス診断市場規模が、2022年に125.9億ドルになり、2027年まで年平均16.37％で成長して269.3億ドルに達すると予測しています。本レポートでは、マルチプレックス診断の世界市場について調査し、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、手法別（高密度マルチプレックスアッセイ、低密度マルチプレックスアッセイ、中密度マルチプレックスアッセイ、超高密度マルチプレックスアッセイ）分析、用途別（アレルギー疾患、自己免疫疾患、循環器内科、感染症、腫瘍）分析、エンドユーザー別（学術研究、臨床研究、診断ラボ、病院、製薬企業）分析、地域別（南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他）分析、競争状況、企業情報などの項目を掲載しています。本書では、Abbott Laboratories、AccuBioTech Co., Ltd.、Agilent Technologies、Becton,Dickinson and Co、Bio-Rad Laboratories, Inc.、BioMérieux SA、Chembio Diagnostic Systems, Inc.、Danaher Corporation、EKF Diagnostics Holdings plc、F. Hoffmann-La Roche Ltd、Hologic, Inc.、Illumina, Inc、Intersect ENT Inc.、LabCorpなどの企業情報が含まれています。 ・序論 ・調査方法 ・エグゼクティブサマリー ・市場概要 ・市場インサイト ・世界のマルチプレックス診断市場規模：手法別 - 高密度マルチプレックスアッセイの市場規模 - 低密度マルチプレックスアッセイの市場規模 - 中密度マルチプレックスアッセイの市場規模 - 超高密度マルチプレックスアッセイの市場規模 ・世界のマルチプレックス診断市場規模：用途別 - アレルギー疾患における市場規模 - 自己免疫疾患における市場規模 - 循環器内科における市場規模 - 感染症における市場規模 - 腫瘍における市場規模 ・世界のマルチプレックス診断市場規模：エンドユーザー別 - 学術研究における市場規模 - 臨床研究における市場規模 - 診断ラボにおける市場規模 - 病院における市場規模 - 製薬企業における市場規模 ・世界のマルチプレックス診断市場規模：地域別 - 南北アメリカのマルチプレックス診断市場規模 アメリカのマルチプレックス診断市場規模 カナダのマルチプレックス診断市場規模 ブラジルのマルチプレックス診断市場規模 ... - アジア太平洋のマルチプレックス診断市場規模 日本のマルチプレックス診断市場規模 中国のマルチプレックス診断市場規模 インドのマルチプレックス診断市場規模 韓国のマルチプレックス診断市場規模 台湾のマルチプレックス診断市場規模 ... -ヨーロッパ/中東/アフリカのマルチプレックス診断市場規模 イギリスのマルチプレックス診断市場規模 ドイツのマルチプレックス診断市場規模 フランスのマルチプレックス診断市場規模 ロシアのマルチプレックス診断市場規模 ... -その他地域のマルチプレックス診断市場規模 ・競争状況 ・企業情報 |
The Global Multiplexed Diagnostics Market size was estimated at USD 10.84 billion in 2021 and expected to reach USD 12.59 billion in 2022, and is projected to grow at a CAGR 16.37% to reach USD 26.93 billion by 2027.
Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.
Market Segmentation & Coverage:
This research report categorizes the Multiplexed Diagnostics to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Method, the market was studied across High Density Multiplexed Assays, Low Density Multiplexed Assays, Mid-density Multiplexed Assays, and Very High Density Multiplexed Assays.
Based on Application, the market was studied across Allergic Diseases, Autoimmune Diseases, Cardiology, Infectious Diseases, and Oncology.
Based on End User, the market was studied across Academic Research, Clinical Research, Diagnostic Labs, Hospitals, and Pharma Companies.
Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Multiplexed Diagnostics market considering the current update on the conflict and its global response.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Multiplexed Diagnostics Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.
Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Multiplexed Diagnostics Market, including Abbott Laboratories, AccuBioTech Co., Ltd., Agilent Technologies, Becton,Dickinson and Co, Bio-Rad Laboratories, Inc., BioMérieux SA, Chembio Diagnostic Systems, Inc., Danaher Corporation, EKF Diagnostics Holdings plc, F. Hoffmann-La Roche Ltd, Hologic, Inc., Illumina, Inc, Intersect ENT Inc., LabCorp, Luminex Corporation, Medtronic PLC, Merck KGaA, MultiplexDX, Inc., Novartis AG, QIAGEN NV, Quest Diagnostics, Roche Diagnostics, Siemens Healthineers, Sysmex Corporation, Thermo Fisher Scientific, Inc., and WerfenLife, S.A..
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Multiplexed Diagnostics Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Multiplexed Diagnostics Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Multiplexed Diagnostics Market?
4. What is the competitive strategic window for opportunities in the Global Multiplexed Diagnostics Market?
5. What are the technology trends and regulatory frameworks in the Global Multiplexed Diagnostics Market?
6. What is the market share of the leading vendors in the Global Multiplexed Diagnostics Market?
7. What modes and strategic moves are considered suitable for entering the Global Multiplexed Diagnostics Market?
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising need for advanced diagnostic technology coupled with increased in prevalence of cancers and other infectious diseases
5.1.1.2. Rise in private-public funding for genomics & personalized medicine
5.1.1.3. Demand for automated equipment & analytical systems
5.1.2. Restraints
5.1.2.1. Limited multiplexing levels and possible cross-sensitivity between single detection sites
5.1.3. Opportunities
5.1.3.1. New opportunity window due to the COVID-19 pandemic
5.1.3.2. Introduction of new and advanced multiplexed diagnostic tools
5.1.4. Challenges
5.1.4.1. Dearth of trained healthcare professionals for handling multiplexed diagnostic equipment
5.2. Cumulative Impact of COVID-19
6. Multiplexed Diagnostics Market, by Method
6.1. Introduction
6.2. High Density Multiplexed Assays
6.3. Low Density Multiplexed Assays
6.4. Mid-density Multiplexed Assays
6.5. Very High Density Multiplexed Assays
7. Multiplexed Diagnostics Market, by Application
7.1. Introduction
7.2. Allergic Diseases
7.3. Autoimmune Diseases
7.4. Cardiology
7.5. Infectious Diseases
7.6. Oncology
8. Multiplexed Diagnostics Market, by End User
8.1. Introduction
8.2. Academic Research
8.3. Clinical Research
8.4. Diagnostic Labs
8.5. Hospitals
8.6. Pharma Companies
9. Americas Multiplexed Diagnostics Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Multiplexed Diagnostics Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Multiplexed Diagnostics Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.1.1. Quadrants
12.1.2. Business Strategy
12.1.3. Product Satisfaction
12.2. Market Ranking Analysis, By Key Player
12.3. Market Share Analysis, By Key Player
12.4. Competitive Scenario
12.4.1. Merger & Acquisition
12.4.2. Agreement, Collaboration, & Partnership
12.4.3. New Product Launch & Enhancement
12.4.4. Investment & Funding
12.4.5. Award, Recognition, & Expansion
13. Company Usability Profiles
13.1. Abbott Laboratories
13.1.1. Business Overview
13.1.2. Key Executives
13.1.3. Product & Services
13.2. AccuBioTech Co., Ltd.
13.2.1. Business Overview
13.2.2. Key Executives
13.2.3. Product & Services
13.3. Agilent Technologies
13.3.1. Business Overview
13.3.2. Key Executives
13.3.3. Product & Services
13.4. Becton,Dickinson and Co
13.4.1. Business Overview
13.4.2. Key Executives
13.4.3. Product & Services
13.5. Bio-Rad Laboratories, Inc.
13.5.1. Business Overview
13.5.2. Key Executives
13.5.3. Product & Services
13.6. BioMérieux SA
13.6.1. Business Overview
13.6.2. Key Executives
13.6.3. Product & Services
13.7. Chembio Diagnostic Systems, Inc.
13.7.1. Business Overview
13.7.2. Key Executives
13.7.3. Product & Services
13.8. Danaher Corporation
13.8.1. Business Overview
13.8.2. Key Executives
13.8.3. Product & Services
13.9. EKF Diagnostics Holdings plc
13.9.1. Business Overview
13.9.2. Key Executives
13.9.3. Product & Services
13.10. F. Hoffmann-La Roche Ltd
13.10.1. Business Overview
13.10.2. Key Executives
13.10.3. Product & Services
13.11. Hologic, Inc.
13.11.1. Business Overview
13.11.2. Key Executives
13.11.3. Product & Services
13.12. Illumina, Inc
13.12.1. Business Overview
13.12.2. Key Executives
13.12.3. Product & Services
13.13. Intersect ENT Inc.
13.13.1. Business Overview
13.13.2. Key Executives
13.13.3. Product & Services
13.14. LabCorp
13.14.1. Business Overview
13.14.2. Key Executives
13.14.3. Product & Services
13.15. Luminex Corporation
13.15.1. Business Overview
13.15.2. Key Executives
13.15.3. Product & Services
13.16. Medtronic PLC
13.16.1. Business Overview
13.16.2. Key Executives
13.16.3. Product & Services
13.17. Merck KGaA
13.17.1. Business Overview
13.17.2. Key Executives
13.17.3. Product & Services
13.18. MultiplexDX, Inc.
13.18.1. Business Overview
13.18.2. Key Executives
13.18.3. Product & Services
13.19. Novartis AG
13.19.1. Business Overview
13.19.2. Key Executives
13.19.3. Product & Services
13.20. QIAGEN NV
13.20.1. Business Overview
13.20.2. Key Executives
13.20.3. Product & Services
13.21. Quest Diagnostics
13.21.1. Business Overview
13.21.2. Key Executives
13.21.3. Product & Services
13.22. Roche Diagnostics
13.22.1. Business Overview
13.22.2. Key Executives
13.22.3. Product & Services
13.23. Siemens Healthineers
13.23.1. Business Overview
13.23.2. Key Executives
13.23.3. Product & Services
13.24. Sysmex Corporation
13.24.1. Business Overview
13.24.2. Key Executives
13.24.3. Product & Services
13.25. Thermo Fisher Scientific, Inc.
13.25.1. Business Overview
13.25.2. Key Executives
13.25.3. Product & Services
13.26. WerfenLife, S.A.
13.26.1. Business Overview
13.26.2. Key Executives
13.26.3. Product & Services
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing